NZVC
Back to the portfolio

Herasight

Herasight provides polygenic genetic screening for embryos created through IVF, combining DNA from embryo biopsies with family medical history to estimate the risk of thousands of conditions, from single-gene disorders to common diseases such as cancer, heart disease and diabetes.

Category
Bio and Healthcare
Fund
NZVC II
Website
www.herasight.com
Herasight

What Herasight does

Herasight's ImputePGTA method genotypes embryos and computes polygenic scores at higher accuracy than earlier approaches, giving prospective parents information to help rank embryos for implantation.

The secret

An embryo biopsy yields very little DNA, which is what held polygenic screening back. ImputePGTA reconstructs the missing genotype accurately enough to score thousands of conditions from that tiny sample, which is the step that moved polygenic prediction from research into a clinical decision.

Why NZVC invested in Herasight

NZVC invested in Herasight from NZVC Fund II. We file the company under Bio and Healthcare on the portfolio wall.

We backed Herasight because polygenic prediction has matured to the point where it can meaningfully inform one of the most consequential decisions a family makes, and few teams have the statistical genetics depth to do it well. The founders combine rigorous research with a clear clinical product, and they publish their methods rather than hide behind marketing. IVF volumes are rising worldwide, and accurate embryo screening sits at the center of that growth.

Watch: ImputePGTA and PGTP Explained: The Latest in Polygenic Embryo Testing with Jonathan Anomaly of Herasight

Herasight in the press

Gluon · All companies · Humata AI